Vertex's cystic fibrosis drug positive in Phase IIa
This article was originally published in Scrip
Vertexhas announced additional positive Phase IIa results for its investigational drug, VX-770, in cystic fibrosis (CF) patients who carry the G551D CFTR (cystic fibrosis transmembrane conductance regulator) gene mutation. The findings were presented at the North American Cystic Fibrosis Conference in Orlando on October 23rd.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.